Skip to main content
. Author manuscript; available in PMC: 2008 Nov 22.
Published in final edited form as: Adv Drug Deliv Rev. 2008 Feb 8;60(8):886–898. doi: 10.1016/j.addr.2007.11.009

Table 2.

Polymer-drug conjugates in clinical trials

Conjugates Indication Status Company References
HPMA-Doxorubicin(PK1; FCE28068) Lung and breast cancers Phase II as of 2002 Pfizer; Cancer Research Campaign UK [47, 48]
HPMA-doxorubicin- galactosamine (PK2, FCE28069) Hepatocellular carcinoma Phase I/II Pfizer; Cancer Research Campaign UK [52]
HPMA-camptothecin (PNU166148) Solid tumors Phase I; discontinued Pfizer; Cancer Research Campaign UK [54]
HPMA-paclitaxel (PNU166945) Solid tumors Phase I; discontinued Pfizer; Cancer Research Campaign UK [55]
HPMA-platinate (AP5346, ProLindac) Ovarian, melanoma, and colorectal cancers Phase I Access Pharmaceutical [56]
PEG-Camptothecin(Pegamotecan) Solid tumors Phase I; discontinued Enzon [58]
PEG-SN38 (EZN-2208) Solid tumors Phase I; initiated as of October 2007 Enzon [59]
Polymeric Micelles(NK911) Pancreatic cancer Phase II Nippon Kayaku, Japan [60]
Cyclodextrin-Based Polymer-CPT (IT-101) Solid tumors Phase I Insert Therapeutics [62]
Carboxymethyldextra n-Exatecan (DE-310) Solid atumors Phase I Daiichi Pharmaceuticals, Japan [63]
PG-TXL (CT-2103, Xyotax) Lung, ovarian, colorectal, breast, and esophageal cancers Phase III Cell Therapeutics [12, 18, 29–37]
PG-camptothecin(CT2106) Colorectal, lung, and ovarian cancers Phase I Cell Therapeutics [69, 70]